PAG
TVTX icon

Private Advisor Group’s Travere Therapeutics TVTX Stock Holding History

Private Advisor Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Buy
15,422
+3,010
+24% +$90K ﹤0.01% 1921
2025
Q4 		$474K Buy
+12,412
New +$404K ﹤0.01% 1855

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Private Advisor Group's TVTX Position: Q1 2026 in Review

Private Advisor Group increased its Travere Therapeutics (TVTX) stake by 24% in Q1 2026, buying an estimated $90K and bringing the position to 15,422 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

Private Advisor Group first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $474K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Private Advisor Group held 15,422 shares of Travere Therapeutics worth $458K as of Q1 2026.
  • Private Advisor Group bought 3,010 Travere Therapeutics shares in Q1 2026, an estimated $90K.
  • Travere Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #1921 holding.
  • Private Advisor Group first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Private Advisor Group's Travere Therapeutics position peaked at $474K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.